1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117: 659-76.
2. Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by Child CG: Philadelphia (PA), Saunders. 1964, pp 50-64.
3. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
5. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo end-stage liver disease. Hepatology 2001; 33: 473-5.
6. Kim MS. Modification of emergency status in deceased donor liver allocation: evidence for Korean model of end-stage liver disease (MELD) system. J Korean Soc Transplant 2016; 30: 51-8.
9. Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol 2011; 54: 462-70.
11. Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981; 1: 673-6.
14. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011; 54: 1297-306.
15. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
16. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004; 4 Suppl 9: 114-31.
17. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-8.
18. Finkenstedt A, Dorn L, Edlinger M, Prokop W, Risch L, Griesmacher A, et al. Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int 2012; 32: 1211-6.
20. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-9; discussion 509-11.
21. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
24. Yoo HY, Edwin D, Thuluvath PJ. Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol 2003; 98: 1395-9.
25. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020; 69: 564-8.
28. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-60.
31. McDiarmid SV, Anand R, Lindblad AS; Principal Investigators and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74: 173-81.
32. SPLIT Research Group. Studies of pediatric liver transplantation (SPLIT): year 2000 outcomes. Transplantation 2001; 72: 463-76.
34. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al; APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int 2019; 13: 353-90. Erratum in: Hepatol Int 2019; 13: 826-8.
37. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37, 1437.e1-9.
38. Olson JC, Kamath PS. Acute-on-chronic liver failure: concept, natural history, and prognosis. Curr Opin Crit Care 2011; 17: 165-9.
41. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. CANONIC Study Investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61: 1038-47.
48. Miller PE, Pawar S, Vaccaro B, McCullough M, Rao P, Ghosh R, et al. Predictive abilities of machine learning techniques may be limited by dataset characteristics: insights from the UNOS database. J Card Fail 2019; 25: 479-83.